VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed\* primary brain tumor, including benign brain tumors (e.g., low-grade glioma)
• * Recurrent or progressive disease OR refractory to standard therapy NOTE: \*Patients with intrinsic brain stem or diffuse optic pathway tumors do not require histological confirmation, but must have clinical and/or radiographic evidence of disease progression
• No bone marrow disease
• PATIENT CHARACTERISTICS:
• Age
• 21 and under
• Performance status
• Karnofsky 50-100% (for patients \> 16 years of age) OR
• Lansky 50-100% (for patients ≤ 16 years of age)
• Life expectancy
• Not specified
• Hematopoietic
• Absolute neutrophil count ≥ 1,000/mm\^3\*
• Platelet count ≥ 100,000/mm\^3\*
• Hemoglobin ≥ 8 g/dL\* NOTE: \*Unsupported
• Hepatic
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• ALT and AST ≤ 2.5 times ULN
• No overt hepatic disease
• Renal
• BUN \< 25 mg/dL
• Creatinine ≤ 1.5 times ULN for age OR
• Glomerular filtration rate \> 70 mL/min
• No overt renal disease
• Cardiovascular
• Shortening fraction ≥ 30% by echocardiogram OR
• Ejection fraction ≥ 50% by gated radionucleotide study
• No clinically significant cardiac arrhythmia by EKG
• No overt cardiac disease
• Pulmonary
• DLCO ≥ 60% of predicted
• Chest X-ray normal (defined as absence of pulmonary infiltrates, pneumonitis, pleural effusion, pulmonary hemorrhage, or fibrosis) AND a resting pulse oximetry reading of \> 94% in room air (for patients who cannot perform the DLCO)
• No overt pulmonary disease
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Neurologic deficits allowed provided there has been no deficit progression for ≥ 1 week before study entry
• No uncontrolled infection
• No known hypersensitivity to polyethylene glycol
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• At least 6 months since prior allogeneic bone marrow or stem cell transplantation
• At least 3 months since prior autologous bone marrow or stem cell transplantation
• More than 1 week since prior colony-stimulating factors (e.g., filgrastim \[G-CSF\], sargramostim \[GM-CSF\], or epoetin alfa)
• At least 3 weeks since prior myelosuppressive anticancer biologic therapy
• No concurrent routine colony-stimulating factors
• Chemotherapy
• At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Endocrine therapy
• Concurrent corticosteroids allowed provided dose is stable or decreasing for ≥ 1 week before study entry
• Radiotherapy
• At least 3 months since prior craniospinal irradiation ≥ 18 Gy
• At least 2 weeks since prior focal irradiation to the primary tumor and/or symptomatic metastatic sites
• Surgery
• Not specified
• Other
• At least 7 days since prior nonmyelosuppressive anticancer therapy
• At least 7 days since prior investigational agents
• Concurrent enzyme-inducing anticonvulsant drugs allowed
• No other concurrent anticancer or experimental agents or therapies